32 results on '"Rao, Ercole"'
Search Results
2. A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
- Author
-
Seung, Edward, Xing, Zhen, Wu, Lan, Rao, Ercole, Cortez-Retamozo, Virna, Ospina, Beatriz, Chen, Liqing, Beil, Christian, Song, Zhili, Zhang, Bailin, Levit, Mikhail, Deng, Gejing, Hebert, Andrew, Kirby, Patrick, Li, Aiqun, Poulton, Emma-Jane, Vicente, Rita, Garrigou, Audrey, Piepenhagen, Peter, Ulinski, Greg, Sanicola-Nadel, Michele, Bangari, Dinesh S., Qiu, Huawei, Pao, Lily, Wiederschain, Dmitri, Wei, Ronnie, Yang, Zhi-yong, and Nabel, Gary J.
- Published
- 2022
- Full Text
- View/download PDF
3. Functional studies with IgM and IgA immunoglobulins: binding to pIgR, FcαμR, FcμR, and CDC activities.
- Author
-
Beyer, Hanna, Sommerfeld, Mark, Grandien, Kaj, Faust, Christine, Tillmann, Bodo, Leuschner, Wulf Dirk, Régnier‐Vigouroux, Anne, Weil, Sandra, Rao, Ercole, and Langer, Thomas
- Subjects
IMMUNOGLOBULIN A ,IMMUNOGLOBULINS ,IMMUNOGLOBULIN M ,IMMUNOGLOBULIN receptors ,IMMUNE system ,IMMUNE response ,IMMUNOGLOBULIN G - Abstract
IgMs are the first antibodies produced by the immune system upon encounter of a possible pathogen and are one of five antibody subclasses in humans. For IgG, the most intensively studied antibody class, the N‐linked glycosylation site located in the Fc‐domain is directly involved in high affinity binding to the respective receptors and initiation of corresponding immune response. IgM molecules have five N‐glycosylation sites and one N‐glycosylation site in the J‐chain, which can be incorporated in IgM or IgA molecules. There is only limited knowledge available concerning the function of these N‐glycosylations in IgMs. To address this question, we produced IgM molecules lacking a particular N‐glycosylation site and tested these variants as well as IgA molecules for binding to the known receptors: the polymeric immunoglobulin receptor (pIgR), the dual receptor for IgA and IgM, FcαμR, and the specific receptor for IgM, FcμR. The single glycosylation sites did not show an impact on expression and multimerization, except for variant N402Q, which could not be expressed. In SPR measurements, no major impact on the binding to the receptors by particular glycosylation sites could be detected. In cellular assays, deglycosylated variants showed some alterations in induction of CDC activity. Most strikingly, we observed also binding of IgA to the FcμR in the same affinity range as IgM, suggesting that this might have a physiological role. To further substantiate the binding of IgA to FcμR we used IgA from different origins and were able to confirm binding of IgA preparations to the FcμR. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation
- Author
-
Wu, Lan, Seung, Edward, Xu, Ling, Rao, Ercole, Lord, Dana M., Wei, Ronnie R., Cortez-Retamozo, Virna, Ospina, Beatriz, Posternak, Valeriya, Ulinski, Gregory, Piepenhagen, Peter, Francesconi, Elisa, El-Murr, Nizar, Beil, Christian, Kirby, Patrick, Li, Aiqun, Fretland, Jennifer, Vicente, Rita, Deng, Gejing, Dabdoubi, Tarik, Cameron, Beatrice, Bertrand, Thomas, Ferrari, Paul, Pouzieux, Stéphanie, Lemoine, Cendrine, Prades, Catherine, Park, Anna, Qiu, Huawei, Song, Zhili, Zhang, Bailin, Sun, Fangxian, Chiron, Marielle, Rao, Srinivas, Radošević, Katarina, Yang, Zhi-yong, and Nabel, Gary J.
- Published
- 2020
- Full Text
- View/download PDF
5. Publisher Correction: A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells
- Author
-
Seung, Edward, Xing, Zhen, Wu, Lan, Rao, Ercole, Cortez-Retamozo, Virna, Ospina, Beatriz, Chen, Liqing, Beil, Christian, Song, Zhili, Zhang, Bailin, Levit, Mikhail, Deng, Gejing, Hebert, Andrew, Kirby, Patrick, Li, Aiqun, Poulton, Emma-Jane, Vicente, Rita, Garrigou, Audrey, Piepenhagen, Peter, Ulinski, Greg, Sanicola-Nadel, Michele, Bangari, Dinesh S., Qiu, Huawei, Pao, Lily, Wiederschain, Dmitri, Wei, Ronnie, Yang, Zhi-yong, and Nabel, Gary J.
- Published
- 2022
- Full Text
- View/download PDF
6. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques
- Author
-
Xu, Ling, Pegu, Amarendra, Rao, Ercole, Doria-Rose, Nicole, Beninga, Jochen, McKee, Krisha, Lord, Dana M., Wei, Ronnie R., Deng, Gejing, Louder, Mark, Schmidt, Stephen D., Mankoff, Zachary, Wu, Lan, Asokan, Mangaiarkarasi, Beil, Christian, Lange, Christian, Leuschner, Wulf Dirk, Kruip, Jochen, Sendak, Rebecca, Kwon, Young Do, Zhou, Tongqing, Chen, Xuejun, Bailer, Robert T., Wang, Keyun, Choe, Misook, Tartaglia, Lawrence J., Barouch, Dan H., O’Dell, Sijy, Todd, John-Paul, Burton, Dennis R., Roederer, Mario, Connors, Mark, Koup, Richard A., Kwong, Peter D., Yang, Zhi-yong, Mascola, John R., and Nabel, Gary J.
- Published
- 2017
7. Molecular Features and Stages of Pulmonary Fibrosis Driven by Type 2 Inflammation.
- Author
-
Mattoo, Hamid, Bangari, Dinesh S., Cummings, Sheila, Humulock, Zachary, Habiel, David, Xu, Ethan Y., Pate, Nathan, Resnick, Robert, Savova, Virginia, Qian, George, Beil, Christian, Rao, Ercole, Nestle, Frank O., Bryce, Paul J., and Subramaniam, Arun
- Subjects
PULMONARY fibrosis ,BISPECIFIC antibodies ,SYSTEMIC scleroderma ,INTERSTITIAL lung diseases ,THERAPEUTICS ,INFLAMMATION - Abstract
Systemic sclerosis (SSc) is a progressive, multiorgan disease with limited treatment options. Although a recent proof-of-concept study using romilkimab or SAR156597, a bispecific IL-4/IL-13 antibody, suggests a direct role of these cytokines in the pathophysiology of SSc, their contributions to the balance between inflammation and fibrosis are unclear. Here, we determine the roles of type 2 inflammation in fibrogenesis using FRA2-Tg (Fos-related antigen 2-overexpressing transgenic) mice, which develop spontaneous, age-dependent progressive lung fibrosis. We defined the molecular signatures of inflammation and fibrosis at three key stages in disease progression, corresponding to preonset, inflammatory dominant, and fibrosis dominant biology, and revealed an early increase in cytokine-cytokine receptor interactions and antigen-processing and presentation pathways followed by enhanced Th2- and M2 macrophage-driven type 2 responses. This type 2 inflammation progressed to extensive fibrotic pathology by 14-18 weeks of age, with these gene signatures overlapping significantly with those seen in the lungs of patients with SSc with interstitial lung disease (ILD). These changes were also evident in the histopathology, which showed perivascular and peribronchiolar inflammation with prominent eosinophilia and accumulation of profibrotic M2-like macrophages followed by rapid progression to fibrosis with thickened alveolar walls with multifocal fibrotic bands and signs of interstitial pneumonia. Critically, treatment with a bispecific antibody targeting IL-4 and IL-13 during the inflammatory phase abrogated the Th2 and M2 responses and led to near-complete abrogation of lung fibrosis. These data recapitulate important features of fibrotic progression in the lungs of patients with SSc-ILD and enhance our understanding of the progressive pathobiology of SSc. This study also further establishes FRA2-Tg mice as a valuable tool for testing future therapeutic agents in SSc-ILD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. SHOT, a SHOX-Related Homeobox Gene, is Implicated in Craniofacial, Brain, Heart, and Limb Development
- Author
-
Blaschke, Rudiger J., Monaghan, A. Paula, Schiller, Simone, Schechinger, Birgit, Rao, Ercole, Padilla-Nash, Hesed, Ried, Thomas, and Rappold, Gudrun A.
- Published
- 1998
9. multivalent antibody assembled from different building blocks using tag/catcher systems: a case study.
- Author
-
Schindler, Christof, Faust, Christine, Sjuts, Hanno, Lange, Christian, Kühn, Jennifer, Dittrich, Werner, Leuschner, Wulf Dirk, Schiebler, Werner, Hofmann, Joachim, Rao, Ercole, and Langer, Thomas
- Subjects
IMMUNOGLOBULINS ,PEPTIDES ,MONOCLONAL antibodies ,CATCHERS (Baseball) ,CARRIER proteins ,BINDING sites ,PROTEIN engineering ,TRANSGLUTAMINASES - Abstract
The field of therapeutic antibodies and, especially bi- or multispecific antibodies, is growing rapidly. Especially for treating cancers, multispecific antibodies are very promising, as there are multiple pathways involved and multispecific antibodies offer the possibility to interfere at two or more sites. Besides being used as therapeutic, multispecific antibodies can be helpful tools in basic research. However, the design and choice of the most appropriate multispecific antibody format are far from trivial. The generation of multispecific antibodies starts with the generation of antibodies directed against the desired targets and then combining the different antigen-binding sites in one molecule. This is a time-consuming and laborious approach since the most suitable geometry cannot be predicted. The SpyTag technology is based on a split-protein system, where a small peptide of said protein, the SpyTag, can bind to the remaining protein, the SpyCatcher. An irreversible isopeptide bond between the SpyTag and the SpyCatcher is formed. A related Tag-Catcher system is the SnoopTag-SnoopCatcher. These systems offer the opportunity to separately produce proteins fused to the tag-peptides and to the catcher-domains and assemble them in vitro. Our goal was to design and produce different antibody fragments, Fab domains and Fc-containing domains, with different tags and/or catchers as building blocks for the assembly of different multivalent antibodies. We have shown that large multivalent antibodies consisting of up to seven building blocks can be prepared. Binding experiments demonstrated that all binding sites in such a large molecule retained their accessibility to their corresponding antigens. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
10. Impact of lipopolysaccharides on cultivation and recombinant protein expression in human embryonal kidney (HEK‐293) cells.
- Author
-
Faust, Christine, Beil, Christian, Dittrich, Werner, Rao, Ercole, and Langer, Thomas
- Subjects
RECOMBINANT proteins ,PROTEIN expression ,LIPOPOLYSACCHARIDES ,ESCHERICHIA coli ,GRAM-negative bacteria - Abstract
The human embryonal kidney 293 cell (HEK‐293) is a widely used expression host for transient gene expression. The genes or plasmids used for the transient transfections are usually propagated and extracted from the gram‐negative bacterium Escherichia coli, the workhorse for molecular biologists. As a gram‐negative bacterium E. coli has an outer membrane (OM) containing lipopolysaccharides (LPS) or endotoxins. LPS are very potent inducers of inflammatory cytokines in the body. In early research phases DNA intended for transient transfections is not routinely checked for LPS‐levels. In this study we addressed the question whether LPS has an impact on the cultivation and production of a recombinant antibody. At high concentrations the presence of LPS has a detrimental impact on cell viability and recombinant protein expression. But low LPS concentrations are tolerated and might even enhance protein expression levels. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. Molecular structure and genetic regulation of SFA, a gene responsible for resistance to formaldehyde in Saccharomyces cerevisiae, and characterization of its protein product
- Author
-
Weimer, Eugen P., Rao, Ercole, and Brendel, Martin
- Published
- 1993
- Full Text
- View/download PDF
12. The Leri–Weill and Turner syndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator
- Author
-
Rao, Ercole, Blaschke, Rüdiger J., Marchini, Antonio, Niesler, Beate, Burnett, Michael, and Rappold, Gudrun A.
- Published
- 2001
13. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using crossover dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
- Author
-
Bonnevaux, Hélène, Guerif, Stephane, Albrecht, Jana, Jouannot, Erwan, De Gallier, Thibaud, Beil, Christian, Lange, Christian, Leuschner, Wulf Dirk, Schneider, Marion, Lemoine, Cendrine, Caron, Anne, Amara, Céline, Barrière, Cédric, Siavellis, Justine, Bardet, Valérie, Luna, Ernesto, Agrawal, Pankaj, Drake, Donald R., Rao, Ercole, and Wonerow, Peter
- Subjects
ACUTE myeloid leukemia ,CELL receptors ,T cells ,BISPECIFIC antibodies ,CANCER cells - Abstract
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse. The cell surface receptor CD123 is highly expressed in blast cells and LSCs from AML patients and is a potential therapeutic target. CD123 cross-over dual-variable domain T-cell engager (CD123-CODV-TCE) is a bispecific antibody with an innovative format. One arm targets the CD3s5 subunit of T-cell co-receptors on the surface of T cells, while the other targets CD123 on malignant cells, leading to cell-specific cytotoxic activity. Here, we describe the preclinical activity of CD123-CODV-TCE. CD123-CODV-TCE effectively binds to human and cynomolgus monkey CD3 and CD123 and is a highly potent T-cell engager. It mediates T-cell activation and T-cell-directed killing of AML cells in vitro. In vivo, CD123-CODV-TCE suppresses AML tumor growth in leukemia xenograft mouse models, where it achieves an effective half-life of 3.2 days, which is a significantly longer half-life compared to other bispecific antibodies with no associated Fc fragment. The in vitro safety profile is as expected for compounds with similar modes of action. These results suggest that CD123-CODV-TCE may be a promising therapy for patients with relapsed/refractory AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
14. Production of a novel heterodimeric two-chain insulin-Fc fusion protein.
- Author
-
Faust, Christine, Ochs, Christian, Korn, Marcus, Werner, Ulrich, Jung, Jennifer, Dittrich, Werner, Schiebler, Werner, Schauder, Rolf, Rao, Ercole, and Langer, Thomas
- Subjects
CHIMERIC proteins ,INSULIN derivatives ,PEPTIDE hormones ,INSULIN ,METABOLIC regulation - Abstract
Insulin is a peptide hormone produced by the pancreas. The physiological role of insulin is the regulation of glucose metabolism. Under certain pathological conditions the insulin levels can be reduced leading to the metabolic disorder diabetes mellitus (DM). For type 1 DM and, dependent on the disease progression for type 2 DM, insulin substitution becomes indispensable. To relieve insulin substitution therapy for patients, novel insulin analogs with pharmacokinetic and pharmacodynamic profiles aiming for long-lasting or fast-acting insulins have been developed. The next step in the evolution of novel insulins should be insulin analogs with a time action profile beyond 1–2 days, preferable up to 1 week. Nowadays, insulin is produced in a recombinant manner. This approach facilitates the design and production of further insulin-analogs or insulin-fusion proteins. The usage of the Fc-domain from immunoglobulin as a fusion partner for therapeutic proteins and peptides is widely used to extend their plasma half-life. Insulin consists of two chains, the A- and B-chain, which are connected by two disulfide-bridges. To produce a novel kind of Fc-fusion protein we have fused the A-chain as well as the B-chain to Fc-fragments containing either 'knob' or 'hole' mutations. The 'knob-into-hole' technique is frequently used to force heterodimerization of the Fc-domain. Using this approach, we were able to produce different variants of two-chain-insulin-Fc-protein (tcI-Fc-protein) variants. The tcI-Fc-fusion variants retained activity as shown in in vitro assays. Finally, prolonged blood glucose lowering activity was demonstrated in normoglycemic rats. Overall, we describe here the production of novel insulin-Fc-fusion proteins with prolonged times of action. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Engineered Fc-glycosylation switch to eliminate antibody effector function.
- Author
-
Zhou, Qun, Jaworski, Julie, Zhou, Yanfeng, Valente, Delphine, Cotton, Joanne, Honey, Denise, Boudanova, Ekaterina, Beninga, Jochen, Rao, Ercole, Wei, Ronnie, Mauriac, Christine, Pan, Clark, Park, Anna, and Qiu, Huawei
- Published
- 2020
- Full Text
- View/download PDF
16. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques.
- Author
-
Ling Xu, Pegu, Amarendra, Rao, Ercole, Doria-Rose, Nicole, Beninga, Jochen, McKee, Krisha, Lord, Dana M., Wei, Ronnie R., Gejing Deng, Louder, Mark, Schmidt, Stephen D., Mankoff, Zachary, Lan Wu, Asokan, Mangaiarkarasi, Beil, Christian, Lange, Christian, Dirk Leuschner, Wulf, Kruip, Jochen, Sendak, Rebecca, and Young Do Kwon
- Published
- 2017
- Full Text
- View/download PDF
17. Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques.
- Author
-
Broeckel, Rebecca, Fox, Julie M., Haese, Nicole, Kreklywich, Craig N., Sukulpovi-Petty, Soila, Legasse, Alfred, Smith, Patricia P., Denton, Michael, Corvey, Carsten, Krishnan, Shiv, Colgin, Lois M. A., Ducore, Rebecca M., Lewis, Anne D., Axthelm, Michael K., Mandron, Marie, Cortez, Pierre, Rothblatt, Jonathan, Rao, Ercole, Focken, Ingo, and Carter, Kara
- Subjects
CHIKUNGUNYA virus ,FEBRILE seizures ,MYALGIA ,MONOCLONAL antibodies ,RHESUS monkeys ,DISEASES - Abstract
Chikungunya virus (CHIKV) is a mosquito-borne virus that causes a febrile syndrome in humans associated with acute and chronic debilitating joint and muscle pain. Currently no licensed vaccines or therapeutics are available to prevent or treat CHIKV infections. We recently isolated a panel of potently neutralizing human monoclonal antibodies (mAbs), one (4N12) of which exhibited prophylactic and post-exposure therapeutic activity against CHIKV in immunocompromised mice. Here, we describe the development of an engineered CHIKV mAb, designated SVIR001, that has similar antigen binding and neutralization profiles to its parent, 4N12. Because therapeutic administration of SVIR001 in immunocompetent mice significantly reduced viral load in joint tissues, we evaluated its efficacy in a rhesus macaque model of CHIKV infection. Rhesus macaques that were treated after infection with SVIR001 showed rapid elimination of viremia and less severe joint infiltration and disease compared to animals treated with SVIR002, an isotype control mAb. SVIR001 reduced viral burden at the site of infection and at distant sites and also diminished the numbers of activated innate immune cells and levels of pro-inflammatory cytokines and chemokines. SVIR001 therapy; however, did not substantively reduce the induction of CHIKV-specific B or T cell responses. Collectively, these results show promising therapeutic activity of a human anti-CHIKV mAb in rhesus macaques and provide proof-of-principle for its possible use in humans to treat active CHIKV infections. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
18. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications.
- Author
-
Steinmetz, Anke, Vallée, François, Beil, Christian, Lange, Christian, Baurin, Nicolas, Beninga, Jochen, Capdevila, Cécile, Corvey, Carsten, Dupuy, Alain, Ferrari, Paul, Rak, Alexey, Wonerow, Peter, Kruip, Jochen, Mikol, Vincent, and Rao, Ercole
- Published
- 2016
- Full Text
- View/download PDF
19. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
- Author
-
Pegu, Amarendra, Xu, Ling, DeMouth, Megan E., Fabozzi, Giulia, March, Kylie, Almasri, Cassandra G., Cully, Michelle D., Wang, Keyun, Yang, Eun Sung, Dias, Joana, Fennessey, Christine M., Hataye, Jason, Wei, Ronnie R., Rao, Ercole, Casazza, Joseph P., Promsote, Wanwisa, Asokan, Mangaiarkarasi, McKee, Krisha, Schmidt, Stephen D., and Chen, Xuejun
- Abstract
Broadly neutralizing antibodies (bNAbs) represent an alternative to drug therapy for the treatment of HIV-1 infection. Immunotherapy with single bNAbs often leads to emergence of escape variants, suggesting a potential benefit of combination bNAb therapy. Here, a trispecific bNAb reduces viremia 100- to 1000-fold in viremic SHIV-infected macaques. After treatment discontinuation, viremia rebounds transiently and returns to low levels, through CD8-mediated immune control. These viruses remain sensitive to the trispecific antibody, despite loss of sensitivity to one of the parental bNAbs. Similarly, the trispecific bNAb suppresses the emergence of resistance in viruses derived from HIV-1-infected subjects, in contrast to parental bNAbs. Trispecific HIV-1 neutralizing antibodies, therefore, mediate potent antiviral activity in vivo and may minimize the potential for immune escape. [Display omitted] • Trispecific bNAbs reduce viremia 100- to 1000-fold in viremic SHIV-infected macaques • After treatment completion in these macaques, long-term viral control is CD8-mediated • Trispecific but not parental bNAbs suppress the emergence of resistant virus in culture Immunotherapy with monoclonal bNAbs leads to emergence of escape variants. Pegu et al. show that trispecific bNAb treatment reduces viremia up to 1000-fold in vivo and limits selection of resistant HIV-1 variants in cell culture. Thus, this antibody has therapeutic potential and may minimize immune escape. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. The Leri–Weill and Turnersyndrome homeobox gene SHOX encodes a cell-type specific transcriptional activator.
- Author
-
Rao, Ercole, Blaschke, RüdigerJ., Marchini, Antonio, Niesler, Beate, Burnett, Michael, and Rappold, GudrunA.
- Published
- 2001
- Full Text
- View/download PDF
21. A novel pseudoautosomal gene encoding a putative GTP-binding protein resides in the vicinity of the Xp/Yp telomere.
- Author
-
Gianfrancesco, Fernando, Esposito, Teresa, Montanini, Luisa, Ciccodicola, Alfredo, Mumm, Steven, Mazzarella, Richard, Rao, Ercole, Giglio, Sabrina, Rappold, Gudrun, and Forabosco, Antonino
- Abstract
Examines a novel pseudoautosomal gene encoding a putative guanosine triphosphate (GTP)-binding protein in the telomere. Relationship between the chromosomal marker map, the cosmid contig and telomeric genes; Factors that control cell proliferation and differentiation; Effect of GTP-coupled proteolysis on the stability of target proteins.
- Published
- 1998
- Full Text
- View/download PDF
22. The human protein kinase gene PKX1 on Xp22.3 displays Xp/Yp homology and is a site of chromosomal instability.
- Author
-
Klink, Albrecht, Schiebel, Katrin, Winkelmann, Martina, Rao, Ercole, Horsthemke, Bernhard, Lüdecke, Hermann-Joset, Claussen, Uwe, Scherer, Gerd, and Rappold, Gudrun
- Published
- 1995
23. SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and...
- Author
-
Schiller, Simone, Reid, Thomas, Blaschke, Rüdiger J., Monaghan, A. Paula, Schechinger, Birgit, Rao, Ercole, Padilla-Nash, Hesed, and Rappold, Gudrun A.
- Subjects
GENETICS ,HOMOLOGY (Biology) - Abstract
Presents a study to identify SHOT, a SHOX-related human gene, which shows a much higher degree of homology to murine OG-12 gene than SHOX. Definition of homeobox genes; Methodology used to conduct the study; Findings of the study.
- Published
- 1998
24. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome.
- Author
-
Rao, Ercole, Weiss, Birgit, Fukami, Maki, Rump, Andreas, Niesler, Beate, Mertz, Annelyse, Muroya, Koji, Binder, Gerhard, Kirsch, Stefan, Winkelmann, Martina, Nordsiek, Gabriele, Heinrich, Udo, Breuning, Martijn H., Ranke, Michael B., Rosenthal, André, Ogata, Tsutomu, and Rappold, Gudrun A.
- Published
- 1997
- Full Text
- View/download PDF
25. A fully automated three-step protein purification procedure for up to five samples using the NGC chromatography system.
- Author
-
Becker, Wolfgang, Scherer, Anne, Faust, Christine, Bauer, David Kornblüh, Scholtes, Simone, Rao, Ercole, Hofmann, Joachim, Schauder, Rolf, and Langer, Thomas
- Subjects
- *
BIOPHARMACEUTICS , *PLASMIDS , *CLONING , *PROTEIN expression , *CHROMATOGRAPHIC analysis - Abstract
Abstract The drug discovery process in the biopharmaceutical industry usually starts with the generation of plasmids coding for certain proteins. Due to advances in cloning techniques the generation of thousands of different plasmids is not a limiting factor anymore. The next step is the expression and evaluation of the proteins. In recent years significant progress has been made in the miniaturization of protein expression and purification. These processes have been adapted to robotic platforms and hundreds of proteins can be expressed and purified in parallel. As a consequence of miniaturization, the protein purification is restricted to a one-step process. In addition the amount of purified protein is usually in the μg-range. This might be suitable if a sensitive initial screening assay is available. However, when larger amounts of proteins are required robotic platforms are no longer appropriate. In addition, a one-step purification procedure is often not sufficient to obtain pure protein preparations. To address this topic we have used the NGC chromatography system for automated purification of up to five samples using a three-step purification procedure. The first chromatographic step is the capture step followed by a desalting step. The final purification was done using size exclusion chromatography. This set-up reduces the overall-time needed for protein production, needs minimal operator invention, is easy to handle and thus increases the throughput. Highlights • Fully automated three step protein purification. • Up to five samples can be processed. • Chromatography system without custom made devices. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. The Short Stature Homeodomain Protein SHOX Induces Cellular Growth Arrest and Apoptosis and Is Expressed in Human Growth Plate Chondrocytes.
- Author
-
Marchini, Antonio, Marttila, Tiina, Winter, Anja, Caldeira, Sandra, Malanchi, Ilaria, Blaschke, Rüdiger J., Häcker, Beate, Rao, Ercole, Karperien, Marcel, Wit, Jan M., Richter, Wiltrud, Tommasino, Massimo, and Rappold, Gudrun A.
- Subjects
- *
GENETIC mutation , *HOMEOBOX genes , *CELL growth , *APOPTOSIS , *GROWTH plate , *CARTILAGE cells , *CELL lines , *FIBROBLASTS , *CELL proliferation - Abstract
Mutations in the homeobox gene SHOX cause growth retardation and the skeletal abnormalities associated with LériWeill, Langer, and Turner syndromes. Little is known about the mechanism underlying these SHOX-related inherited disorders of bone formation. Here we demonstrate that SHOX expression in osteogenic stable cell lines, primary oral fibroblasts, and primary chondrocytes leads to cell cycle arrest and apoptosis. These events are associated with alterations in the expression of several cellular genes, including pRB, p53, and the cyclin kinase inhibitors p21cip1 and p27Kip1. A SHOX mutant, such as seen in Léri-Weill syndrome patients, does not display these activities of the wild type protein. We have also shown that endogenous SHOX is mainly expressed in hypertrophic/apoptotic chondrocytes of the growth plate, strongly suggesting that the protein plays a direct role in regulating the differentiation of these cells. This study provides the first insight into the biological function of SHOX as regulator of cellular proliferation and viability and relates these cellular events to the phenotypic consequences of SHOX deficiency. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
27. A Member of a Gene Family on Xp22.3, VCX-A, Is Deleted in Patients with X-Linked Nonspecific Mental Retardation.
- Author
-
Fukami, Maki, Kirsch, Stefan, Schiller, Simone, Richter, Alexandra, Benes, Vladimir, Franco, Brunella, Muroya, Koji, Rao, Ercole, Merker, Sabine, Niesler, Beate, Ballabio, Andrea, Ansorge, Wilhelm, Ogata, Tsutomu, and Rappold, Gudrun A.
- Subjects
- *
X chromosome , *INTELLECTUAL disabilities - Abstract
Examines a member of a gene family on variably charged X chromosome in CRI-S232A (VCX-A) in patients with X-linked nonspecific mental retardation. Derivation of cosmids and plasmid artificial chromosomes; Identification of the genomic sequence of VCX gene; Structural features and expression profile of VCX gene.
- Published
- 2000
- Full Text
- View/download PDF
28. A multivalent antibody assembled from different building blocks using tag/catcher systems: a case study.
- Author
-
Schindler C, Faust C, Sjuts H, Lange C, Kühn J, Dittrich W, Leuschner WD, Schiebler W, Hofmann J, Rao E, and Langer T
- Subjects
- Antibodies genetics, Peptides chemistry
- Abstract
The field of therapeutic antibodies and, especially bi- or multispecific antibodies, is growing rapidly. Especially for treating cancers, multispecific antibodies are very promising, as there are multiple pathways involved and multispecific antibodies offer the possibility to interfere at two or more sites. Besides being used as therapeutic, multispecific antibodies can be helpful tools in basic research. However, the design and choice of the most appropriate multispecific antibody format are far from trivial. The generation of multispecific antibodies starts with the generation of antibodies directed against the desired targets and then combining the different antigen-binding sites in one molecule. This is a time-consuming and laborious approach since the most suitable geometry cannot be predicted. The SpyTag technology is based on a split-protein system, where a small peptide of said protein, the SpyTag, can bind to the remaining protein, the SpyCatcher. An irreversible isopeptide bond between the SpyTag and the SpyCatcher is formed. A related Tag-Catcher system is the SnoopTag-SnoopCatcher. These systems offer the opportunity to separately produce proteins fused to the tag-peptides and to the catcher-domains and assemble them in vitro. Our goal was to design and produce different antibody fragments, Fab domains and Fc-containing domains, with different tags and/or catchers as building blocks for the assembly of different multivalent antibodies. We have shown that large multivalent antibodies consisting of up to seven building blocks can be prepared. Binding experiments demonstrated that all binding sites in such a large molecule retained their accessibility to their corresponding antigens., (© The Author(s) 2022. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
29. Pre-clinical development of a novel CD3-CD123 bispecific T-cell engager using cross-over dual-variable domain (CODV) format for acute myeloid leukemia (AML) treatment.
- Author
-
Bonnevaux H, Guerif S, Albrecht J, Jouannot E, De Gallier T, Beil C, Lange C, Leuschner WD, Schneider M, Lemoine C, Caron A, Amara C, Barrière C, Siavellis J, Bardet V, Luna E, Agrawal P, Drake DR, Rao E, Wonerow P, Carrez C, Blanc V, Hsu K, Wiederschain D, Fraenkel PG, and Virone-Oddos A
- Subjects
- Animals, CD3 Complex, Humans, Interleukin-3 Receptor alpha Subunit, Macaca fascicularis, Mice, T-Lymphocytes, Antibodies, Bispecific, Leukemia, Myeloid, Acute drug therapy
- Abstract
Novel therapies are needed for effective treatment of AML. In the relapsed setting, prognosis is very poor despite salvage treatment with chemotherapy. Evidence suggests that leukemic stem cells (LSCs) cause relapse. The cell surface receptor CD123 is highly expressed in blast cells and LSCs from AML patients and is a potential therapeutic target. CD123 cross-over dual-variable domain T-cell engager (CD123-CODV-TCE) is a bispecific antibody with an innovative format. One arm targets the CD3εδ subunit of T-cell co-receptors on the surface of T cells, while the other targets CD123 on malignant cells, leading to cell-specific cytotoxic activity. Here, we describe the preclinical activity of CD123-CODV-TCE. CD123-CODV-TCE effectively binds to human and cynomolgus monkey CD3 and CD123 and is a highly potent T-cell engager. It mediates T-cell activation and T-cell-directed killing of AML cells in vitro. In vivo, CD123-CODV-TCE suppresses AML tumor growth in leukemia xenograft mouse models, where it achieves an effective half-life of 3.2 days, which is a significantly longer half-life compared to other bispecific antibodies with no associated Fc fragment. The in vitro safety profile is as expected for compounds with similar modes of action. These results suggest that CD123-CODV-TCE may be a promising therapy for patients with relapsed/refractory AML., Competing Interests: HB, SG, JA, EJ, TDG, CB, CL, WDL, MS, CL, AC, CA, CB, AV, ER, PW, CC: Employees of Sanofi. JS: employee of University Paris 7. VBa: employee of University Versailles Saint Quentin en Yvelines and Assistance Publique Hôpitaux de Paris; VBl, KH, DW, PGF: was an employee of Sanofi at the time this work was performed. EL, PA, DRDIII: Employee of Sanofi-Pasteur, Orlando FL, USA., (© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2021
- Full Text
- View/download PDF
30. Production of a novel heterodimeric two-chain insulin-Fc fusion protein.
- Author
-
Faust C, Ochs C, Korn M, Werner U, Jung J, Dittrich W, Schiebler W, Schauder R, Rao E, and Langer T
- Subjects
- Animals, Humans, Male, Rats, Rats, Sprague-Dawley, Blood Glucose metabolism, Immunoglobulin Fc Fragments biosynthesis, Immunoglobulin Fc Fragments genetics, Immunoglobulin Fc Fragments pharmacology, Insulin biosynthesis, Insulin genetics, Insulin pharmacology, Recombinant Fusion Proteins biosynthesis, Recombinant Fusion Proteins genetics, Recombinant Fusion Proteins pharmacology
- Abstract
Insulin is a peptide hormone produced by the pancreas. The physiological role of insulin is the regulation of glucose metabolism. Under certain pathological conditions the insulin levels can be reduced leading to the metabolic disorder diabetes mellitus (DM). For type 1 DM and, dependent on the disease progression for type 2 DM, insulin substitution becomes indispensable. To relieve insulin substitution therapy for patients, novel insulin analogs with pharmacokinetic and pharmacodynamic profiles aiming for long-lasting or fast-acting insulins have been developed. The next step in the evolution of novel insulins should be insulin analogs with a time action profile beyond 1-2 days, preferable up to 1 week. Nowadays, insulin is produced in a recombinant manner. This approach facilitates the design and production of further insulin-analogs or insulin-fusion proteins. The usage of the Fc-domain from immunoglobulin as a fusion partner for therapeutic proteins and peptides is widely used to extend their plasma half-life. Insulin consists of two chains, the A- and B-chain, which are connected by two disulfide-bridges. To produce a novel kind of Fc-fusion protein we have fused the A-chain as well as the B-chain to Fc-fragments containing either 'knob' or 'hole' mutations. The 'knob-into-hole' technique is frequently used to force heterodimerization of the Fc-domain. Using this approach, we were able to produce different variants of two-chain-insulin-Fc-protein (tcI-Fc-protein) variants. The tcI-Fc-fusion variants retained activity as shown in in vitro assays. Finally, prolonged blood glucose lowering activity was demonstrated in normoglycemic rats. Overall, we describe here the production of novel insulin-Fc-fusion proteins with prolonged times of action., (© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
31. Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model.
- Author
-
Do TM, Capdevila C, Pradier L, Blanchard V, Lopez-Grancha M, Schussler N, Steinmetz A, Beninga J, Boulay D, Dugay P, Verdier P, Aubin N, Dargazanli G, Chaves C, Genet E, Lossouarn Y, Loux C, Michoux F, Moindrot N, Chanut F, Gury T, Eyquem S, Valente D, Bergis O, Rao E, and Lesuisse D
- Abstract
Most antibodies display very low brain exposure due to the blood-brain barrier (BBB) preventing their entry into brain parenchyma. Transferrin receptor (TfR) has been used previously to ferry antibodies to the brain by using different formats of bispecific constructs. Tetravalent bispecific tandem immunoglobulin Gs (IgGs) (TBTIs) containing two paratopes for both TfR and protofibrillar forms of amyloid-beta (Aβ) peptide were constructed and shown to display higher brain penetration than the parent anti-Aβ antibody. Additional structure-based mutations on the TfR paratopes further increased brain exposure, with maximal enhancement up to 13-fold in wild-type mice and an additional 4-5-fold in transgenic (Tg) mice harboring amyloid plaques, the main target of our amyloid antibody. Parenchymal target engagement of extracellular amyloid plaques was demonstrated using in vivo and ex vivo fluorescence imaging as well as histological methods. The best candidates were selected for a chronic study in an amyloid precursor protein (APP) Tg mouse model showing efficacy at reducing brain amyloid load at a lower dose than the corresponding monospecific antibody. TBTIs represent a promising format for enhancing IgG brain penetration using a symmetrical construct and keeping bivalency of the payload antibody., (© 2020 Sanofi.)
- Published
- 2020
- Full Text
- View/download PDF
32. biAb Mediated Restoration of the Linkage between Dystroglycan and Laminin-211 as a Therapeutic Approach for α-Dystroglycanopathies.
- Author
-
Gumlaw N, Sevigny LM, Zhao H, Luo Z, Bangari DS, Masterjohn E, Chen Y, McDonald B, Magnay M, Travaline T, Yoshida-Moriguchi T, Fan W, Reczek D, Stefano JE, Qiu H, Beil C, Lange C, Rao E, Lukason M, Barry E, Brondyk WH, Zhu Y, and Cheng SH
- Subjects
- Animals, Antibodies, Bispecific immunology, Antibodies, Bispecific metabolism, Disease Models, Animal, Dystroglycans immunology, Gene Expression, Humans, Immunohistochemistry, Injections, Intramuscular, Laminin genetics, Laminin immunology, Mice, Mice, Knockout, Models, Biological, Muscle, Skeletal drug effects, Muscle, Skeletal metabolism, Muscle, Skeletal pathology, Protein Binding drug effects, Protein Interaction Domains and Motifs genetics, Sarcolemma drug effects, Sarcolemma metabolism, Walker-Warburg Syndrome drug therapy, Walker-Warburg Syndrome etiology, Antibodies, Bispecific pharmacology, Dystroglycans metabolism, Laminin metabolism, Walker-Warburg Syndrome metabolism
- Abstract
Patients with α-dystroglycanopathies, a subgroup of rare congenital muscular dystrophies, present with a spectrum of clinical manifestations that includes muscular dystrophy as well as CNS and ocular abnormalities. Although patients with α-dystroglycanopathies are genetically heterogeneous, they share a common defect of aberrant post-translational glycosylation modification of the dystroglycan alpha-subunit, which renders it defective in binding to several extracellular ligands such as laminin-211 in skeletal muscles, agrin in neuromuscular junctions, neurexin in the CNS, and pikachurin in the eye, leading to various symptoms. The genetic heterogeneity associated with the development of α-dystroglycanopathies poses significant challenges to developing a generalized treatment to address the spectrum of genetic defects. Here, we propose the development of a bispecific antibody (biAb) that functions as a surrogate molecular linker to reconnect laminin-211 and the dystroglycan beta-subunit to ameliorate sarcolemmal fragility, a primary pathology in patients with α-dystroglycan-related muscular dystrophies. We show that the treatment of LARGE
myd-3J mice, an α-dystroglycanopathy model, with the biAb improved muscle function and protected muscles from exercise-induced damage. These results demonstrate the viability of a biAb that binds to laminin-211 and dystroglycan simultaneously as a potential treatment for patients with α-dystroglycanopathy., (Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.